Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Trump Renews Push for Most-Favored-Nation Drug Pricing. What It All Means
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Akebia Therapeutics Reports Strong Q1 2025 Performance
Akebia Projects Vafseo Rollout to Double Patient Access by Q4 2025
Akebia Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Akebia Therapeutics | 10-Q: Q1 2025 Earnings Report
Akebia GAAP EPS of $0.03 Beats by $0.07, Revenue of $57.34M Beats by $12.81M
Akebia Therapeutics | 8-K: Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics 1Q Rev $57.3M >AKBA
Express News | Akebia Therapeutics Q1 EPS USD 0.03 Vs. IBES Estimate USD -0.04
Express News | Akebia Therapeutics Q1 Net Income USD 6.112 Million Vs. IBES Estimate USD -10.9 Million
Express News | Akebia Therapeutics Q1 Operating Expenses USD 36.197 Million
Here Are the Major Earnings Before the Open Tomorrow
Leerink Partners Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7
Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and CVRx (CVRX)
Earnings Preview: AKBA to Report Financial Results Pre-market on May 08
Express News | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights